Racial differences in serum prostate specific antigen (PSA) values in men with and without prostate cancer have been observed but have yet to be explained. We aimed to determine if ethnic variations in the rate of metabolism of PSA could explain the different levels of PSA found in African-American and Caucasian men. In a prospective fashion, patients diagnosed with biopsy-proven clinically localized adenocarcinoma of the prostate and scheduled for radical prostatectomy were selected for the study. Eleven patients (six Caucasian, five African-American) were enrolled in the study. All patients demonstrated normal liver and renal function. Sera for total PSA were obtained at the following time intervals: preoperative (within 3 months of operation), time 0 (at time of prostate removal), 1, 4, 8, 24, 48, 72, 168 and 336 h after removal of the prostate. A log -linear regression model was then used to determine the metabolic clearance rate and half-life of serum total PSA. There were no statistically significant differences between Caucasian and African-American patients with regard to age, PSA prior to surgery, prostate weight, Gleason sum and PSA half-life. The metabolic clearance of total PSA followed first order kinetics. When comparing serum PSA levels expressed as a fraction of the baseline PSA, Caucasian and AfricanAmerican patients demonstrated similar rates of metabolism. This study found similar rates of elimination of serum total PSA between African-Americans and Caucasians. These findings suggest that the rate of metabolism of PSA is similar for these groups. Further studies are needed to explain racial differences of serum PSA in patients with and without prostate cancer.
Introduction
African-Americans have a higher incidence and mortality for prostate cancer in relation to Caucasians. 1 Racial differences in serum prostate specific antigen (PSA) values in men with and without prostate cancer have been observed but have yet to be explained. 2 -5 Earlier reports suggested that larger tumor volumes found in black patients were the primary explanation for the higher PSA at presentation. 4 More recently, Pettaway et al reported that black patients had higher pre-operative serum PSA levels at advanced pathological stages (pT3 þ and pT3c) despite similar total gland weight and tumor volume. 6 Likewise, Moul and colleagues demonstrated that pretreatment PSA levels were higher in black patients who underwent radical prostatectomy after controlling for 3D tumor volume, benign gland volume, age, stage and Gleason sum. 3 We aimed to determine the rate of metabolism or elimination of PSA from the serum of men with localized prostate cancer following radical prostatectomy. Our hypothesis was that differences in serum PSA levels between different ethnic groups is at least partially explained by differences in the rate of metabolism and elimination of PSA from the serum.
Materials and methods

Patients
This study was approved by the institutional review board of the Dallas Veterans Affairs Hospital. In a prospective fashion, patients diagnosed with biopsy-proven clinically localized adenocarcinoma of the prostate and scheduled for radical prostatectomy were selected for the study. Eleven patients (six Caucasian, five African-American) were enrolled in the study. All patients demonstrated normal liver function (prothrombin time, total albumin, total protein) and normal renal function (serum creatinine) prior to their radical prostatectomy. Table 1 shows the ethnicity, Gleason sum, lymph node status, seminal vesicle status, final pathologic stage and prostate weight for all patients.
In order to exclude the possibility of residual tumor influencing the PSA elimination kinetic, the following criteria had to be fulfilled: (1) negative lymph nodes on final pathologic evaluation; (2) negative preoperative metastatic workup (chest X-ray, bone scan for preoperative PSA > 10, liver function tests); (3) no evidence of gross residual tumor at the time of operation.
The patients were all placed on the same clinical pathway postoperatively. This included intravenous crystalloid fluids at a rate of 125 cc/h for the first 24 h postoperatively. The patients were initiated on a clear liquid diet and advanced as tolerated. All men were in good condition pre-operatively and had a good nutritional state. There were no significant perioperative complications and no episodes of organ failure or return to the operating room within the observation period. One patient received one unit of packed red blood cells within 2 h of operation. Of those nine patients who had serum PSA levels at 3 months follow-up available, all were undetectable.
Total PSA serum half-life determination Sera for total PSA were obtained at the following time intervals: preoperative (within 3 months of operation), time 0 (at time of prostate removal), 1, 4, 8, 24, 48, 72, 168 and 336 h after removal of the prostate. The number of samples drawn from each patient varied but each patient had at least seven samples drawn. There was also occasional variation from the exact hour in the initial design but the time of the blood draw was carefully recorded for each serum sample, and calculations were made accordingly. The serum total PSA was measured using the Elecys 2000 machine (Roche Corp., Switzerland). A log -linear regression model was then used to determine the metabolic clearance rate and half-life of serum total PSA. A t-test was used to compare the results for the Caucasian and African-American patients with P < 0.05 as a measure of statistical significance.
Results
The serum total PSA half-life was calculated for each patient and is shown in Table 2 . At baseline, there were no statistically significant differences between Caucasian and African-American patients in regard to age, PSA prior to surgery, prostate weight, Gleason sum and PSA half-life (Table 3) .
The serum total PSA levels for the patients as a function of hours (common log) is shown in Figure 1 . The metabolic clearance of total PSA followed first order kinetics. When comparing serum PSA levels expressed as a fraction of the baseline PSA, Caucasian and African-American patients demonstrated similar rates of metabolism ( Figure 2 ). 
Discussion
PSA has become a very important test for detecting, staging and monitoring prostate cancer. 7 The initial reports on the rate of elimination of PSA after radical prostatectomy determined a half-life for total PSA in the range of 2 -3 days. 8, 9 While racial differences in serum PSA values in men with and without prostate cancer have been observed, differences in PSA half-life in AfricanAmericans and Caucasians have not been evaluated. 2 -5 If African-Americans metabolize PSA at a different rate than Caucasians, this could explain differences in PSA levels.
There have been multiple papers describing a two phase model of PSA elimination with an initial rapid phase, likely representing elimination of free PSA, and a prolonged phase, primarily representing metabolism of conjugated PSA. 10 -13 Several researchers found that the liver is the most likely site of metabolism for conjugated PSA, while the kidney excretes most of the free PSA. 14 -16 For the purposes of this study, we were interested in evaluating potential differences in PSA metabolism between African-Americans and Caucasians. Such differences could provide an explanation for the differences in baseline PSA between African-Americans and Caucasians. Measurement of serum total PSA levels post-prostatectomy allows determination of the rate of metabolism of PSA without need of differentiating elimination of free and conjugated PSA. The patients in this study demonstrated first order kinetics in the elimination of serum total PSA and racial differences in the half-life of total PSA were not noted. Interestingly, we did not note an increase in initial levels of PSA after radical prostatectomy, but this was not the focus of our study.
A limitation of this study is the small number of patients evaluated and it is possible that small differences between groups would be missed in the analysis. At the same time, there is significant uniformity between T1/2 for all patients in the study regardless of race.
This study population had no distant metastases with all patients undergoing preoperative metastatic work-up and with negative lymph nodes on final pathology. Two patients had extracapsular extension and two patients had positive margins but it is unlikely that the tumor burden would be significant enough to significantly alter the PSA levels. All the patients had appropriate decreases in their serum PSA levels. The one patient that received one unit of packed red blood cells also had a linear decrease in serum PSA levels. Other researchers have not found significant differences in PSA levels based on blood transfusion. 11 There were also no significant racial differences in PSA at presentation, prostate weight, or Gleason sum.
While the reason for the increased baseline PSA levels in African-Americans is not understood, several hypotheses have been proposed. Sex hormone differences have been noted between Caucasians and African-Americans. Ross and colleagues found that African-Americans had mean testosterone concentration and sex hormone binding globulin values that were 11% and 9% higher than Caucasians, respectively. 17 At the same time, they did not find differences in dihydrotestosterone metabolites between Caucasians and African-Americans. Furthermore, the mean testosterone concentrations of Japanese students (602 ng/ml) were intermediate between Caucasians (575 ng/ml) and African-Americans (640 ng/ml). Vijayakumar et al evaluated patients with prostate cancer and found that serum free testosterone, androstenedione, luteinizing hormone and prolactin did not PSA clearance after radical prostatectomy Y Lotan and CG Roehrborn influence PSA levels in multivariate analysis. 18 There were no differences in serum hormone levels between Caucasians and African-Americans with the exception that luteinizing hormone levels were lower in AfricanAmericans.
Other investigators have studied the role of the androgen receptor in prostate cancer. Irvine and co-workers discovered differences in the distribution of CAG and GGC microsatellites of the androgen receptor gene between African-American, Caucasian and Asian men. 19 African-American men had a statistically significant greater distribution of short CAG and GGC repeats. The authors postulated that the androgen receptor gene may play a role in the development of prostate cancer and that the length of the CAG and GGC repeats directly influence androgen receptor function.
Further factors that have been evaluated include differences in tumor stage and grade at presentation. Moul et al, 20 Powell et al 21 and Pettaway et al 6 reported that African-American men presented with higher PSA levels and more advanced pathologic stage than Caucasians. On the other hand, Moul et al found that pretreatment PSA levels were higher in African-American patients who underwent radical prostatectomy after controlling for 3D tumor volume, benign gland volume, age, stage and Gleason sum. 3 Likewise, Pettaway et al suggested that racial differences in the biology of prostate cancer may exist as African-American patients with advancing pathologic stage had higher preoperative serum PSA levels despite similar total gland weight and tumor volume. 6 
Conclusions
This study found similar rates of elimination of serum total PSA between African-Americans and Caucasians. These findings suggest that the rate of metabolism of PSA is similar for these groups. Further studies are needed to explain racial differences of serum PSA in patients with and without prostate cancer.
